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E-mail: tatjana.avsic@mf.uni-lj.siIn recent decades, vector-borne diseases have emerged as a
threat to global health. Vectors such as ticks, mosquitoes, sand
ﬂies and mammals are responsible for the transmission of
various pathogens causing diseases in humans and animals. The
occurrence of vector-borne pathogens, and thus the risk posed
to humans and animals, greatly depends on the distribution of
suitable vectors, which is inﬂuenced by climate factors, envi-
ronmental conditions, and anthropogenic factors. The interplay
and complexity of these heterogeneous factors is not yet
completely understood [1]. Many vector-transmitted pathogens
have been introduced into new regions, and some endemic
vector-borne diseases have increased in incidence. Several new
pathogens have been discovered, and outbreaks of new clinical
syndromes have been identiﬁed. Molecular methods have
signiﬁcantly contributed to the increased number of recently
recognized microorganisms transmitted by vectors. Some of
these newly identiﬁed microorganisms are readily linked to
human disease, whereas others are not yet known to cause
disease in humans, or have been recognized as human patho-
gens years after their discovery.
In the current themed section of CMI, four articles describe
the discovery of new vector-transmitted pathogens. The ﬁrst
contribution concerns severe fever with thrombocytopenia
syndrome (SFTS), a newly discovered emerging infectious dis-
ease caused by a novel phlebovirus, named SFTS virus, trans-
mitted to humans and animals by ticks. The second article gives
an overview of another tick-borne pathogen, Candidatus Neo-
ehrlichia mikurensis, an intracellular bacterium that has only
recently been implicated as a causative agent of neoehrlichiosis.
The third article reports on a relapsing fever group spirochete,
Borrelia miyamotoi, which has been known to be transmitted by
ixodid tick species for two decades, but only recently have
human cases of infection with B. miyamotoi been found. The
fourth article describes the relevance of Plasmodium knowlesi, a
mosquito-borne blood parasite of the Southeast Asian ma-
caques that has entered the human population.Clinical Microbiology and Infection © 2015 European Society of CDexin Li reviews SFTS that has been discovered in China.
This emerging disease presents with high fever, thrombocyto-
penia, leukopenia, and gastrointestinal disorders, and a high
case-fatality rate was ﬁrst recognized in rural areas of China in
2009 [2,3]. The viral aetiology of the disease was conﬁrmed by
isolation of a novel phlebovirus from patients with acute dis-
ease. A new virus, designated SFTS virus, is a member of the
family Bunyaviridae, genus Phlebovirus. The disease was recently
reported in Japan and South Korea [4,5], and another, geneti-
cally closely related phlebovirus, Heartland virus, was found to
be the causative agent in cases with severe illness with
thrombocytopenia in the USA [6]. Although ticks are generally
considered to be the vector of SFTS, person-to-person trans-
mission through direct contact with contaminated blood has
also been reported [7]. SFTS varies in severity from mild to
severe disease, including neurological manifestations, haemor-
rhages, and multi-organ failure with disseminated intravascular
coagulation. The case-fatality rate is as high as 17%, and the
majority of SFTS deaths in China have occurred in the elderly
[8]. The disease can be clinically confused with other infectious
diseases, including human granulocytic anaplasmosis and hae-
morrhagic fever with renal syndrome. Currently, there is no
speciﬁc treatment other than supportive therapy. The author
concludes that there is a need for speciﬁc antiviral drugs and
protective vaccines, as SFTS is difﬁcult to control, owing to the
complex transmission chain between ticks, vertebrates and
ticks in a changing environment [9].
Two interesting examples of reversed disease discovery, i.e.
the identiﬁcation of disease cases years after the vector-borne
microorganism was ﬁrst recognized, include C. Neoehrlichia
mickurensis and B. miyamotoi [10]. C. Neoehrlichia mikurensis is
a newly emerging tick-transmitted pathogen that belongs to the
genus Neoehrlichia in the Anaplasmataceae family. As the bac-
terium has not been cultivated so far, its life cycle, morphology
and cellular tropism are mainly presumed. In her review,
Wennerås comprehensively describes the epidemiology of C.
Neoehrlichia mickurensis infection among several species of
ticks and rodents in Europe and Asia, where rodents seems to
be its natural host reservoirs [11]. The ﬁrst description of
human infection with C. Neoehrlichia mikurensis appeared a
decade after the microorganism was initially detected in ticksClin Microbiol Infect 2015; 21: 611–613
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immunocompromised patients, may have a severe course, with
vascular and thromboembolic involvement [13]. Treatment
with doxycycline usually leads to the rapid and full recovery of
patients. Finally, the author concludes that much about C.
Neoehrlichia mikurensis remains unexplained, so successful
culture of the bacterium is needed.
Another tick-transmitted bacterium that has recently been
recognized as a human pathogen is B. miyamotoi. This relapsing
fever group spirochete was discovered 20 years ago in ixodid
ticks in Japan, and later in other tick species that are known
vectors of Lyme disease in Europe and the USA [14,15]. In the
present themed section, Krause et al. show how the bacterium
was ‘unattractive’ until the ﬁrst human cases of B. miyamotoi
infection were reported 4 years ago in Russia; subsequently,
additional cases were discovered in Europe, Asia, the USA, and
Japan [16,17]. The clinical manifestations of B. miyamotoi infec-
tion are non-speciﬁc, except for relapsing fever. Symptoms
usually resolve after a week of speciﬁc therapy that includes
commonly used antibiotics, which are also used for the treat-
ment of Lyme disease. The authors suggest that the same
preventive measures that are used for other tick-transmitted
diseases should be effective for B. miyamotoi [17].
In the last article of this themed issue, Cox-Singh and Millar
show how it has recently become evident that P. knowlesi, a
parasite that characteristically infects forest macaque monkeys,
can be transmitted to humans by mosquitoes [18]. Since the
ﬁrst discovery of human natural infection with P. knowlesi in
2004 in the Sarawak state of Borneo, this type of malaria has
become the most prevalent in Malaysia, and is widespread in
Southeast Asia [19,20]. The transmission cycle of this parasite is
zoonotic and is restricted to the habitat of the natural hosts and
vectors; thus, humans entering jungle settings are at risk. Until
molecular methods became routinely available, human in-
fections with P. knowlesi were misdiagnosed as infection with
the morphologically similar Plasmodium malariae. Malaria caused
by the former organism presents with a spectrum of clinical
disease, including severe, complicated forms. Although the
disease can be potentially fatal, P. knowlesi malaria can be suc-
cessfully treated with antimalarial drugs [21]. The authors
critically conclude that the natural transmission of P. knowlesi is
under pressure because of its ongoing entry into the human
population; therefore, permanent monitoring of transmission
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